Kraig Biocraft: Second Production Facility to deliver Spider Silk to European-based global Luxury Market
New architecture lays foundation for higher output, continuous batch production, and prepares company for spider silk delivery to european-based global luxury market leader.
Kraig Biocraft Laboratories, a global leader in spider silk technology, announced the addition of a second parallel production facility, three new advanced spider silk strains, and the immediate launch of a new diapausing system for production. This marks three critical advancements in the Company’s high-performance spider silk manufacturing and commercialization to significantly increase production yields and spun silk quality.
Kraig Labs completed the development of three new spider silk strains, which are now in the field. These strains, developed over the last year, were designed to complement the Company’s existing BAM-1 hybrid by improving hybrid vigor and increasing silk yield. One of these stains was designed as a replacement for an existing BAM-1 parent lines. Two of these strains were bred to produce silkworms suitable for controlled diapause.
Diapause refers to the silkworm’s natural wintering period, a process which can be replicated with a 90-day cold treatment of the silkworm eggs. Diapausing silkworm strains are the gold standard for producing premium silk. One of the Company’s key initial target customers is a widely-renowned producer of the world’s finest fabrics and garments, crafted from the highest-quality fibers. Kraig Labs is committed to meeting those standards with its spider silk and the shift to diapausing egg production, along with the addition of a second facility, are key drivers in achieving that goal and increasing production.
Thus far, the Company’s production center has operated under a batch production model, bypassing diapause and limiting production to 8 or 9 batches per year. The shift to parallel facilities and the diapausing of eggs (artificial wintering utilizing cold storage treatment) will enable nearly continuous production. These two facilities will operate in tandem to feed that production. While egg production from one facility enters cold storage, the second facility will prepare the next rearing cycle, ensuring a continuous flow of eggs to supply production operations. This new collaborative production system will dramatically expand production capacity far beyond what any single facility could produce independently.
As Kraig Labs rolls out these significant improvements to its operations, the company is undertaking a production transition period, which includes a 90-day cold treatment cycle for the new diapausing hybrid eggs. This wintering process is widely recognized for yielding stronger, finer silk and significantly larger cocoons than non-diapausing silk. Over the next several months, operational emphasis will shift away from finished silk production and focus on expanding parent line populations and generating the next round of hybrid eggs that Kraig Labs plans to begin releasing in the fourth quarter.
“Deploying two separate rearing centers for our parent lines is a key part of our strategy to build a reliable and scalable supply chain that can address the demand for spider silk and support year-round production,” said Kim Thompson, Founder and CEO of Kraig Labs. “This plan, which is the brainchild of our chief sericulture expert, Dr. Kumar, will provide the throughput necessary to support large-scale commercial production and a buffer against potential disruption.”
In parallel with these advancements in production operations, Kraig Labs announced it has completed the latest batch of BAM-1 finished spider silk. With this newest batch of finished silk complete, the company has now accumulated approximately one-third of the total spider silk required to fulfill a material request from a globally renowned European fashion house.
“This latest batch brings us another step closer to delivering premium spider silk materials to one of the most recognized names in fashion. The shift to a diapausing hybrid system reflects our long-term vision to deliver the highest quality spider silk at commercial scale,” said Rice. “By making this investment in time, infrastructure, and production strategy, we are positioning ourselves to meet the demand we see forming.”
Kraig Biocraft Laboratories